Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

[Guest guest]

http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6W7C-513363B-6 & _user=1\

0 & _coverDate=03%2F31%2F2011 & _rdoc=15 & _fmt=high & _orig=browse & _origin=browse & _zone\

=rslt_list_item & _srch=doc-info(%23toc%236623%232011%23999459996%232908743%23FLA%\

23display%23Volume) & _cdi=6623 & _sort=d & _docanchor= & _ct=41 & _acct=C000050221 & _versi\

on=1 & _urlVersion=0 & _userid=10 & md5=68f6f775eb072d035246254854fc79d4 & searchtype=a

Journal of Hepatology

Volume 54, Issue 3, March 2011, Pages 449-454

--------------------------------------------------------------------------------

doi:10.1016/j.jhep.2010.07.046 | How to Cite or Link Using DOI

Copyright © 2010 European Association for the Study of the Liver Published by

Elsevier Ireland Ltd.

Permissions & Reprints

Research Article

Kinetics of hepatitis B surface antigen differ between treatment with

peginterferon and entecavir

References and further reading may be available for this article. To view

references and further reading you must purchase this article.

Jurriën G.P. Reijnders1, §, Rijckborst1, §, Milan J. Sonneveld1,

M.J. Scherbeijn2, A.B. Boucher2, Bettina E. Hansen1, 3 and Harry

L.A. Janssen1, ,

1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical

Center, Rotterdam, The Netherlands

2 Department of Virology, Erasmus MC, University Medical Center, Rotterdam, The

Netherlands

3 Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam,

The Netherlands

Received 9 April 2010; revised 8 July 2010; accepted 12 July 2010. Available

online 23 September 2010.

Background & Aims

We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in

patients with chronic hepatitis B virus (HBV) infection during peginterferon

(PEG-IFN) and entecavir (ETV) monotherapy.

Methods

HBsAg was quantified (Abbott ARCHITECT) at baseline and during antiviral therapy

(weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-) positive patients

treated with ETV (n = 33) or PEG-IFN (n = 61) and in HBeAg-negative patients

treated with ETV (n = 37) or PEG-IFN (n = 69).

Results

Within the HBeAg-positive population, patients treated with PEG-IFN tended to

have a steeper HBsAg decline than ETV-treated patients (mean decline 0.94 versus

0.38 log IU/ml at week 48, p = 0.07 for comparison of the slope of HBsAg

decline). The HBsAg decline was larger in those patients who became HBeAg

negative, irrespective of the treatment regimen. A decline in HBsAg was confined

to ETV-treated patients with elevated baseline alanine aminotransferase (ALT)

levels, whereas HBsAg decline was not associated with baseline ALT in patients

treated with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a

significant HBsAg decline, while HBsAg did not decrease in ETV-treated patients

(0.56 versus −0.10 log IU/ml, p <0.001). Both in HBeAg-positive and

HBeAg-negative patients, the decline in serum HBV DNA was larger in patients who

received ETV as compared to patients treated with PEG-IFN.

Conclusions

In HBeAg-positive patients, the decline in serum HBsAg is mainly confined to

patients who clear HBeAg, by either PEG-IFN or ETV treatment. In HBeAg-negative

patients, PEG-IFN therapy resulted in a significant reduction in HBsAg levels,

whereas HBsAg did not decrease in ETV-treated patients.

[Guest guest]

http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6W7C-513363B-6 & _user=1\

0 & _coverDate=03%2F31%2F2011 & _rdoc=15 & _fmt=high & _orig=browse & _origin=browse & _zone\

=rslt_list_item & _srch=doc-info(%23toc%236623%232011%23999459996%232908743%23FLA%\

23display%23Volume) & _cdi=6623 & _sort=d & _docanchor= & _ct=41 & _acct=C000050221 & _versi\

on=1 & _urlVersion=0 & _userid=10 & md5=68f6f775eb072d035246254854fc79d4 & searchtype=a

Journal of Hepatology

Volume 54, Issue 3, March 2011, Pages 449-454

--------------------------------------------------------------------------------

doi:10.1016/j.jhep.2010.07.046 | How to Cite or Link Using DOI

Copyright © 2010 European Association for the Study of the Liver Published by

Elsevier Ireland Ltd.

Permissions & Reprints

Research Article

Kinetics of hepatitis B surface antigen differ between treatment with

peginterferon and entecavir

References and further reading may be available for this article. To view

references and further reading you must purchase this article.

Jurriën G.P. Reijnders1, §, Rijckborst1, §, Milan J. Sonneveld1,

M.J. Scherbeijn2, A.B. Boucher2, Bettina E. Hansen1, 3 and Harry

L.A. Janssen1, ,

1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical

Center, Rotterdam, The Netherlands

2 Department of Virology, Erasmus MC, University Medical Center, Rotterdam, The

Netherlands

3 Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam,

The Netherlands

Received 9 April 2010; revised 8 July 2010; accepted 12 July 2010. Available

online 23 September 2010.

Background & Aims

We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in

patients with chronic hepatitis B virus (HBV) infection during peginterferon

(PEG-IFN) and entecavir (ETV) monotherapy.

Methods

HBsAg was quantified (Abbott ARCHITECT) at baseline and during antiviral therapy

(weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-) positive patients

treated with ETV (n = 33) or PEG-IFN (n = 61) and in HBeAg-negative patients

treated with ETV (n = 37) or PEG-IFN (n = 69).

Results

Within the HBeAg-positive population, patients treated with PEG-IFN tended to

have a steeper HBsAg decline than ETV-treated patients (mean decline 0.94 versus

0.38 log IU/ml at week 48, p = 0.07 for comparison of the slope of HBsAg

decline). The HBsAg decline was larger in those patients who became HBeAg

negative, irrespective of the treatment regimen. A decline in HBsAg was confined

to ETV-treated patients with elevated baseline alanine aminotransferase (ALT)

levels, whereas HBsAg decline was not associated with baseline ALT in patients

treated with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a

significant HBsAg decline, while HBsAg did not decrease in ETV-treated patients

(0.56 versus −0.10 log IU/ml, p <0.001). Both in HBeAg-positive and

HBeAg-negative patients, the decline in serum HBV DNA was larger in patients who

received ETV as compared to patients treated with PEG-IFN.

Conclusions

In HBeAg-positive patients, the decline in serum HBsAg is mainly confined to

patients who clear HBeAg, by either PEG-IFN or ETV treatment. In HBeAg-negative

patients, PEG-IFN therapy resulted in a significant reduction in HBsAg levels,

whereas HBsAg did not decrease in ETV-treated patients.

[Guest guest]

http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6W7C-513363B-6 & _user=1\

0 & _coverDate=03%2F31%2F2011 & _rdoc=15 & _fmt=high & _orig=browse & _origin=browse & _zone\

=rslt_list_item & _srch=doc-info(%23toc%236623%232011%23999459996%232908743%23FLA%\

23display%23Volume) & _cdi=6623 & _sort=d & _docanchor= & _ct=41 & _acct=C000050221 & _versi\

on=1 & _urlVersion=0 & _userid=10 & md5=68f6f775eb072d035246254854fc79d4 & searchtype=a

Journal of Hepatology

Volume 54, Issue 3, March 2011, Pages 449-454

--------------------------------------------------------------------------------

doi:10.1016/j.jhep.2010.07.046 | How to Cite or Link Using DOI

Copyright © 2010 European Association for the Study of the Liver Published by

Elsevier Ireland Ltd.

Permissions & Reprints

Research Article

Kinetics of hepatitis B surface antigen differ between treatment with

peginterferon and entecavir

References and further reading may be available for this article. To view

references and further reading you must purchase this article.

Jurriën G.P. Reijnders1, §, Rijckborst1, §, Milan J. Sonneveld1,

M.J. Scherbeijn2, A.B. Boucher2, Bettina E. Hansen1, 3 and Harry

L.A. Janssen1, ,

1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical

Center, Rotterdam, The Netherlands

2 Department of Virology, Erasmus MC, University Medical Center, Rotterdam, The

Netherlands

3 Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam,

The Netherlands

Received 9 April 2010; revised 8 July 2010; accepted 12 July 2010. Available

online 23 September 2010.

Background & Aims

We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in

patients with chronic hepatitis B virus (HBV) infection during peginterferon

(PEG-IFN) and entecavir (ETV) monotherapy.

Methods

HBsAg was quantified (Abbott ARCHITECT) at baseline and during antiviral therapy

(weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-) positive patients

treated with ETV (n = 33) or PEG-IFN (n = 61) and in HBeAg-negative patients

treated with ETV (n = 37) or PEG-IFN (n = 69).

Results

Within the HBeAg-positive population, patients treated with PEG-IFN tended to

have a steeper HBsAg decline than ETV-treated patients (mean decline 0.94 versus

0.38 log IU/ml at week 48, p = 0.07 for comparison of the slope of HBsAg

decline). The HBsAg decline was larger in those patients who became HBeAg

negative, irrespective of the treatment regimen. A decline in HBsAg was confined

to ETV-treated patients with elevated baseline alanine aminotransferase (ALT)

levels, whereas HBsAg decline was not associated with baseline ALT in patients

treated with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a

significant HBsAg decline, while HBsAg did not decrease in ETV-treated patients

(0.56 versus −0.10 log IU/ml, p <0.001). Both in HBeAg-positive and

HBeAg-negative patients, the decline in serum HBV DNA was larger in patients who

received ETV as compared to patients treated with PEG-IFN.

Conclusions

In HBeAg-positive patients, the decline in serum HBsAg is mainly confined to

patients who clear HBeAg, by either PEG-IFN or ETV treatment. In HBeAg-negative

patients, PEG-IFN therapy resulted in a significant reduction in HBsAg levels,

whereas HBsAg did not decrease in ETV-treated patients.

[Guest guest]

http://www.sciencedirect.com/science?_ob=ArticleURL & _udi=B6W7C-513363B-6 & _user=1\

0 & _coverDate=03%2F31%2F2011 & _rdoc=15 & _fmt=high & _orig=browse & _origin=browse & _zone\

=rslt_list_item & _srch=doc-info(%23toc%236623%232011%23999459996%232908743%23FLA%\

23display%23Volume) & _cdi=6623 & _sort=d & _docanchor= & _ct=41 & _acct=C000050221 & _versi\

on=1 & _urlVersion=0 & _userid=10 & md5=68f6f775eb072d035246254854fc79d4 & searchtype=a

Journal of Hepatology

Volume 54, Issue 3, March 2011, Pages 449-454

--------------------------------------------------------------------------------

doi:10.1016/j.jhep.2010.07.046 | How to Cite or Link Using DOI

Copyright © 2010 European Association for the Study of the Liver Published by

Elsevier Ireland Ltd.

Permissions & Reprints

Research Article

Kinetics of hepatitis B surface antigen differ between treatment with

peginterferon and entecavir

References and further reading may be available for this article. To view

references and further reading you must purchase this article.

Jurriën G.P. Reijnders1, §, Rijckborst1, §, Milan J. Sonneveld1,

M.J. Scherbeijn2, A.B. Boucher2, Bettina E. Hansen1, 3 and Harry

L.A. Janssen1, ,

1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical

Center, Rotterdam, The Netherlands

2 Department of Virology, Erasmus MC, University Medical Center, Rotterdam, The

Netherlands

3 Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam,

The Netherlands

Received 9 April 2010; revised 8 July 2010; accepted 12 July 2010. Available

online 23 September 2010.

Background & Aims

We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in

patients with chronic hepatitis B virus (HBV) infection during peginterferon

(PEG-IFN) and entecavir (ETV) monotherapy.

Methods

HBsAg was quantified (Abbott ARCHITECT) at baseline and during antiviral therapy

(weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-) positive patients

treated with ETV (n = 33) or PEG-IFN (n = 61) and in HBeAg-negative patients

treated with ETV (n = 37) or PEG-IFN (n = 69).

Results

Within the HBeAg-positive population, patients treated with PEG-IFN tended to

have a steeper HBsAg decline than ETV-treated patients (mean decline 0.94 versus

0.38 log IU/ml at week 48, p = 0.07 for comparison of the slope of HBsAg

decline). The HBsAg decline was larger in those patients who became HBeAg

negative, irrespective of the treatment regimen. A decline in HBsAg was confined

to ETV-treated patients with elevated baseline alanine aminotransferase (ALT)

levels, whereas HBsAg decline was not associated with baseline ALT in patients

treated with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a

significant HBsAg decline, while HBsAg did not decrease in ETV-treated patients

(0.56 versus −0.10 log IU/ml, p <0.001). Both in HBeAg-positive and

HBeAg-negative patients, the decline in serum HBV DNA was larger in patients who

received ETV as compared to patients treated with PEG-IFN.

Conclusions

In HBeAg-positive patients, the decline in serum HBsAg is mainly confined to

patients who clear HBeAg, by either PEG-IFN or ETV treatment. In HBeAg-negative

patients, PEG-IFN therapy resulted in a significant reduction in HBsAg levels,

whereas HBsAg did not decrease in ETV-treated patients.